Education
About Us
Working with TipRanks
Follow Us
Cannara Biotech (TSE:LOVE)
:LOVE
Total Valuation
Cannara Biotech has a market cap or net worth of $115.12M. The enterprise value is ―.
Market Cap$115.12M
Enterprise Value―
Share Statistics
Cannara Biotech has 90,643,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding90,643,950
Owned by Insiders46.34%
Owned by Institutions―
Financial Efficiency
Cannara Biotech’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 10.55%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)10.55%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee177.33K
Profits Per Employee13.97K
Employee Count461
Asset Turnover0.53
Inventory Turnover1.30
Valuation Ratios
The current PE Ratio of Cannara Biotech is 9.51. Cannara Biotech’s PEG ratio is 0.01.
PE Ratio9.51
PS Ratio0.00
PB Ratio1.33
Price to Fair Value0.70
Price to FCF35.71
Price to Operating Cash Flow12.80
PEG Ratio0.01
Income Statement
In the last 12 months, Cannara Biotech had revenue of 81.75M and earned 6.44M in profits. Earnings per share was 0.07.
Revenue81.75M
Gross Profit29.79M
Operating Income10.08M
Pretax Income4.48M
Net Income6.44M
EBITDA15.16M
Earnings Per Share (EPS)0.07
Cash Flow
In the last 12 months, operating cash flow was 9.77M and capital expenditures -6.26M, giving a free cash flow of 3.50M billion.
Operating Cash Flow9.77M
Free Cash Flow3.50M
Free Cash Flow per Share0.04
Dividends & Yields
Cannara Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.03
52-Week Price Change61.73%
50-Day Moving Average1.32
200-Day Moving Average0.92
Relative Strength Index (RSI)47.86
Average Volume (3m)54.26K
Important Dates
Cannara Biotech upcoming earnings date is Jul 24, 2025, TBA Not Confirmed.
Last Earnings DateApr 28, 2025
Next Earnings DateJul 24, 2025
Ex-Dividend Date―
Financial Position
Cannara Biotech as a current ratio of 2.50, with Debt / Equity ratio of 51.88%
Current Ratio2.50
Quick Ratio1.01
Debt to Market Cap0.78
Net Debt to EBITDA2.75
Interest Coverage Ratio1.78
Taxes
In the past 12 months, Cannara Biotech has paid -1.95M in taxes.
Income Tax-1.95M
Effective Tax Rate-0.44
Enterprise Valuation
Cannara Biotech EV to EBITDA ratio is 6.79, with an EV/FCF ratio of 32.03.
EV to Sales1.26
EV to EBITDA6.79
EV to Free Cash Flow32.03
EV to Operating Cash Flow9.64
Balance Sheet
Cannara Biotech has $5.06M in cash and marketable securities with C$48.86M in debt, giving a net cash position of $43.81M billion.
Cash & Marketable Securities$5.06M
Total DebtC$48.86M
Net Cash$43.81M
Net Cash Per Share$0.48
Tangible Book Value Per Share$0.98
Margins
Gross margin is 41.96%, with operating margin of 12.33%, and net profit margin of 7.88%.
Gross Margin41.96%
Operating Margin12.33%
Pretax Margin5.49%
Net Profit Margin7.88%
EBITDA Margin18.55%
EBIT Margin10.78%
Analyst Forecast
The average price target for Cannara Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast28.97%
EPS Growth Forecast112.89%